David R. Spigel, MD

David Spigel, M.D., is a board-certified medical oncologist and the chief scientific officer at Sarah Cannon Research Institute. As chief scientific officer, Dr. Spigel oversees Sarah Cannon's clinical trial program, working with the research physician leaders and pharma/biotech partners to ensure cutting-edge therapies are available to patients.

Dr. Spigel is a board member of the Association of Community Cancer Centers and a member of the American Society of Clinical Oncology, Amer

My goal is to help patients determine the treatment options that best fit their circumstances, lifestyle and wishes. Ultimately, I want them to have a good quality of life while fighting cancer .

I care about my patient’s welfare and recommend the treatments and clinical trials that I think are the best options for them. I know that many of my patients are going through the scariest time in their lives and I do whatever I can to support them. I find my work to be very rewarding.

When patients participate in a clinical trial, they receive the standard of care or better. They have the opportunity to try a new treatment that may work better than the current standard of care. Not only does this research help the generations behind us, but it can also help current trial participants now.

Research is such a crucial component of oncology—it gives us hope. There’s never been a more exciting time in the field of cancer research.